ATXS, contraction in the corporate conduct during the most recent fiscal period

As the earnings season of the October to December 31 2022 goes on, many corporations have reported the earnings. In the thick of it, are many constituents of the Major Pharmaceutical Preparations industry. And today, ATXS reported operating deficit of $-14.29 millions, for the October to December 31 2022 span.

The operating deficit has worsened from $-9.507 millions, from the fourth quarter of 2021. But more importantly, the market observers are speculating, if the ATXSs' could begin to cite the revenue.


The company is seeking various corporate policies, in attempt to assure steady service. During the same period the shortfalls, which the Astria Therapeutics Inc has dealt with amid the expanding stage, have expanded to $-13.264 millions, from $-9.491 millions, relative to the same period a year ago.

Even more, the Astria Therapeutics Inc claimed as well net deficit of $-51.83 millions and for the fiscal year 2022, Revenues of $0.00 millions.

Major Pharmaceutical Preparations Astria Therapeutics Inc has decreased it's deficit per share to $-3.55 from $-24.58 in the previous fiscal year, while by 0 % from $0.00 millions a year before.

Astria Therapeutics Inc is expected to report next financial results on May 11, 2023.

Astria Therapeutics Inc's ROA

Astria Therapeutics Inc's ROA

Other ATXS's Earnings Reports